Missed the CON call, unfortunately. Did he mention why they have sold on average only 3 sales per clinical site (of which there are 12), over the last 3 months since FDA approval? That's one 1 unit per month from these trained up sites who are familiar with the procedures given they were involved in trials.
They haven't hit anywhere near manufacturing limits, so I hope they're not using the production commissioning as an excuse.
I have also become a little wary of the management communication. I'm not sure what low ball sales expectations they had such that they are exceeding these expectations at only 1 sale per site per month.
With 17 trained sales guys on board now, they should each be hitting 10's of units per week from here onward, I would have thought.
Missed the CON call, unfortunately. Did he mention why they have...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.684M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 29583410 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 59394450 | 39 |
View Market Depth
| Last trade - 16.13pm 20/06/2025 (20 minute delay) ? |
| AXP (ASX) Chart |
Day chart unavailable